Summary The expression of mRNA for the epidermal growth factor (EGF) receptor, EGF and transforming growth factor a (TGF-a) was determined in 76 malignant, six borderline and 15 benign primary ovarian tumours using the reverse transcriptase-polymerase chain reaction and related to clinical and pathological parameters. Of the malignant tumours, 70% (53/76) expressed EGF receptor mRNA, 31% (23/75) expressed EGF mRNA and 35% (26/75) expressed TGF-a mRNA. For the borderline tumours, four of six (67%) expressed EGF receptor mRNA, 1/6 (17%) expressed TGF-a mRNA and none expressed EGF mRNA. Finally, 33% (5/15) of the benign tumours expressed EGF receptor mRNA, whereas 40% (6/15) expressed EGF mRNA and 7% (1/15) expressed TGF-a mRNA. The presence of the EGF receptor in malignant tumours was associated with that of TGF-a (P = 0.0015) but not with EGF (P = 1.00), whereas there was no relationship between the presence of EGF and TGF-a (P = 1.00). EGF receptor mRNA expression was significantly and positively associated with serous histology (P = 0.006) but not with stage or grade. Neither EGF nor TGF-a showed any link with histological subtype or stage. The survival of patients with malignant tumours possessing EGF receptor mRNA was significantly reduced compared with that of patients whose tumours were negative (P = 0.030 for all malignant tumours; P= 0.007 for malignant epithelial tumours only). In contrast, neither the expression of TGF-a nor EGF was related to survival. These data suggest that the presence of EGF receptor mRNA is associated with poor prognosis in primary ovarian cancer.
Ovarian cancer is the most fatal gynaecological cancer in the UK, resulting in approximately 4000 deaths per annum (La Vecchia et al., 1992) . The biological factors that regulate the growth of this disease are poorly defined, although evidence is accumulating that members of the epidermal growth factor (EGF) family are implicated in the regulation of cell proliferation in ovarian tumours. In epithelial cells, both EGF and its structural homologue, transforming growth factor a (TGF-a) stimulate proliferation. TGF-a is a 50 amino acid protein that binds to the EGF receptor, and produces biological effects barely distinguishable from those of EGF. Although TGF-a was named for its ability to transform certain types of cells in culture, it is produced by normal as well as malignant cells (Berchuck and Bast, 1993) . The EGF receptor is a 170 kDa glycosylated membranespanning protein that has served as a prototype for studies of tyrosine kinase receptors. Both EGF and TGF-a bind to the extracellular domain of the EGF receptor with equal affinity (Berchuck and Bast, 1993) . Using model systems of ovarian cancer, EGF and TGF-a have been shown to be growth stimulatory to ovarian cancer cells in vitro (Morishige et al., 1991; Rodriguez et al., 1991; Scambia et al., 1991; Crew et al., 1992; Zhou and Leung, 1992) . Antibodies directed against either TGF-a or the EGF receptor can inhibit the proliferation of ovarian cancer cell lines that both produce TGF-cx and possess the EGF receptor; this is consistent with an autocrine growth stimulation pathway (Morishige et al., 1991; Jindal et al., 1994) . Previous studies investigating the presence of EGF receptor in ovarian tumours, using either ligand binding (Bauknecht et al., 1988; Battaglia et al., 1989;  Correspondence: SP Langdon *Present address: Glasgow University Department of Surgery, Level II, Queen Elizabeth Building, Glasgow Royal Infirmary, Glasgow G31 2ER, UK Owens et al., 1991a; Henzen-Logmans et al., 1992) immunohistochemical technology Morishige et al., 1991; Henzen-Logmans et al., 1992) or both (Owens et al., 1992) , have indicated that this receptor is commonly present with incidence rates varying from 33% to 75% (Bauknecht et al., 1988 (Bauknecht et al., , 1993 Battaglia et al., 1989; Berchuck et al., 1991; Morishige et al., 1991; Owens et al., 1991a; Henzen-Logmans et al., 1992) . The levels of EGF receptor have been claimed to be higher in malignant ovarian tumours than in benign tumours or the normal ovary Owens and Leake, 1993) but perhaps the strongest suggestion of a biological role for EGF-like factors derives from reports that the presence of EGF receptor protein in ovarian tumours may be related to patient prognosis (Bauknecht et al., 1988; Battaglia, 1989; Foekens et al., 1990; Berchuck et al., 1991; Scambia et al., 1992) , although this has not been a universal finding (Bauknecht et al., 1990 ; Van der Burg et al., 1993) .
In the present study, we have examined the mRNA expression of the EGF receptor, EGF and TGF-oc using the reverse transcriptase-polymerase chain reaction (RT-PCR) in 97 ovarian tumours. The expression of these growth factors and their receptors has been related to clinical and pathological parameters to evaluate further the role of the EGF receptor and its ligands in ovarian disease. The amplification reaction was carried out over 40 cycles with the following parameters: step 1, 94°C for 38 s; step 2, 50°C for 53 s; step 3, 72°C for 68 s. For the final cycle, the 72°C step was extended to 7 min to ensure that all transcripts were full length. The primers used in these reactions are listed in Table I. PCR products were visualised after electrophoresis on polyacrylamide gels and staining with ethidium bromide. Tumours were scored as positive for EGF receptor, EGF or TGF-cx when a PCR product of the correct molecular size was amplified and identified (by eye) following electrophoresis. Samples were sized using a 100 bp ladder (Gibco, UK). As an additional control, PCR of a known housekeeping gene y-actin was performed to establish the integrity of transcribed RNA.
Patients and methods
The identities of transcript sequences were confirmed by Southern blot analysis using specific [32P]5'-end labelled probes (25-mers) targeted to unique sequences within the transcripts (Table I) .
Statistics
Differences between subgroups in contingency tables were analysed by the Fisher's exact test. Differences of survival used the graphical Kaplan-Meier method and groups were compared using the log-rank test. To assess if the mRNA variables were independently prognostic for survival Cox regression analysis was used with stage, residual disease, grade and histology included among the variables in the initial step of a backward stepwise selection procedure. The results are given as hazard ratios. A hazard ratio of 2 for a given marker indicates that the risk of death at any time for a patient with that marker is twice that of a patient without the marker, all other prognostic variables being the same (Cox, 1972) . Figure 1 and confirmation of the sequence of the transcript was obtained by use of a 32P-labelled probe, targeted to a unique sequence within the transcript (illustrated in Figure 1 The relationship between mRNA expression and survival was investigated in the malignant group overall (survival data available for 70 of the 76 patients) and in the epithelial malignant subgroup (n =60) (Table IV) (P= 0.007) (Figure 2) . As with the malignant group overall, the association between survival with EGF mRNA (P=0.113) and TGF-a (P=0.119) was non-significant, whereas stage, amount of residual disease, grade and histology were all linked to survival in this group of patients (Table IV) (Bauknecht et al., 1988; Battaglia et al., 1989; Foekens et al., 1990; Berchuck et al., 1991; Scambia et al., 1992 al., 1988 , 1993 B; 1989; Foekens et al., 1990; Berchuck et al., IS et al., 1991; Owens et al., 1991a; Berns et al., Logmans et al., 1992) . When mRNA for the was examined by Northern blot analysis, it wz present in 75% tumour samples (Kohler Bauknecht et al., 1993) . Our finding of 70% EGF receptor mRNA is therefore consiste reports. We found EGF mRNA present in 31 tumours, which is again consistent with the fin and Leake (1993), who reported the protein tc 30% of malignant tumours. Our incidence of for TGF-a mRNA is lower than the 66% incid ac mRNA determined by Northern blot anal) al., Bauknecht et al., 1993) or the 89% for the protein by Owens et al. (1991b (Bauknecht et al., 1988) , however extension of this data set to include more patients reversed this finding (Bauknecht et al., 1990) . In a subsequent report, the same authors found that ovarian tumours expressing high concentrations of EGF receptor and TGF-a responded better initially to chemotherapy than those with negative or low levels of these proteins, however recurrence was also rapid in the same group (Bauknecht et al., 1993 ).
In conclusion, this is the first report on the use of RT -PCR methodology to determine expression of the EGF family in ovarian cancer. Expression of EGF receptor mRNA was found to be associated with serous histology and a poor survival. These data support the view that expression of the EGF receptor plays a key role in the biology of this disease.
